Mohamad Mostafa Habli*
Hypertension is both a cause and consequence of Chronic Kidney Disease (CKD), significantly accelerating its progression and increasing morbidity and mortality. Accurate Blood Pressure (BP) measurement and management are critical for mitigating these risks. This review examines the complex pathophysiology of hypertension in CKD and evaluates current BP management guidelines, including the 2017 AHA/ACC and 2021 KDIGO recommendations. Emphasis is placed on the importance of individualized treatment plans incorporating lifestyle modifications, RAAS inhibitors, calcium channel blockers, diuretics, and novel agents such as SGLT2 inhibitors. The review also explores emerging pharmacological therapies and their potential benefits. Effective BP control in CKD patients not only slows disease progression but also reduces cardiovascular risk, underscoring the need for a patient-specific approach to optimize clinical outcomes. Further research is required to refine treatment protocols and enhance therapeutic efficacy in this high-risk population.
Поделиться этой статьей
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi 